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Beyond their important role in hemostasis, platelets play a crucial role in inflammatory
diseases. This becomes apparent during sepsis, where platelet count and activation
correlate with disease outcome and survival. Sepsis is caused by a dysregulated host
response to infection, leading to organ dysfunction, permanent disabilities, or death.
During sepsis, tissue injury results from the concomitant uncontrolled activation of the
complement, coagulation, and inflammatory systems as well as platelet dysfunction.
The balance between the systemic inflammatory response syndrome (SIRS) and the
compensatory anti-inflammatory response (CARS) regulates sepsis outcome. Persistent
thrombocytopenia is considered as an independent risk factor of mortality in sepsis,
although it is still unclear whether the drop in platelet count is the cause or the
consequence of sepsis severity. The role of platelets in sepsis development and
progression was addressed in different experimental in vivo models, particularly in mice,
that represent various aspects of human sepsis. The immunomodulatory function of
platelets depends on the experimental model, time, and type of infection. Understanding
the molecular mechanism of platelet regulation in inflammation could bring us one
step closer to understand this important aspect of primary hemostasis which drives
thrombotic as well as bleeding complications in patients with sterile and infectious
inflammation. In this review, we summarize the current understanding of the contribution
of platelets to sepsis severity and outcome. We highlight the differences between platelet
receptors in mice and humans and discuss the potential and limitations of animal models
to study platelet-related functions in sepsis.
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SEPSIS
Sepsis is a highly complex life-threatening syndrome of organ dysfunction caused by dysregulated
inflammatory host response to an overwhelming systemic infection (1). Sepsis is typically
manifested by an early dominant hyper-inflammatory phase, the systemic inflammatory
response syndrome (SIRS), characterized by fever and hyper-metabolism, which can eventually
lead to septic shock. This pro-inflammatory state is followed by or co-exists with a
compensatory anti-inflammatory response (CARS) and immunosuppression, leading to secondary
complications (2).
According to the Sepsis-3 guidelines, sepsis is diagnosed by the Sequential Organ Failure
Assessment (SOFA) score, which assesses organ dysfunction and risk of mortality (1). Sepsis is
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the primary cause of death from infection and occurs in 6–30% of
patients in intensive care units (ICUs) (3). In-hospital mortality
of patients with sepsis exceeds 10%, but increases to over 40% in
severe cases which deteriorate into septic shock (1).
While early and effective medical interventions have managed
to lower mortality over the last three decades (4), sepsis incidence
is actually rising which might reflect the aging population in
developed countries and increases the total number of patients
suffering from or dying of sepsis.
Pathology of Sepsis
Normal host response to pathogen invasion involves a complex
process to localize and confine microbes, while initiating repair
processes of injured tissue. Microbial components can be
recognized by germline-encoded pattern recognition receptors
(PRR) on host immune cells, which bind pathogen-associated
molecular patterns (PAMPs) of microorganisms or danger-
associated molecular patterns (DAMPs) that are released
from injured tissues during the inflammatory insult. PRRs
can be further divided in toll-like receptors (TLRs), C-type
lectin receptors (CLRs), nucleotide-binding oligomerization
domain (NOD)-like receptors, and retinoic acid-inducible gene
I (RIG-I)-like receptors (RLRs) (5).
Engagement of PRRs elicits various signaling cascades
essential for the neutralization of pathogens. A central event
in this process is the activation of cytosolic nuclear factor-κB
(NF-κB). Activated NF-κB translocates from the cytoplasm to
the nucleus, where it binds to transcription sites and induces
activation of a plethora of genes involved in inflammatory host
response, including pro-inflammatory cytokines, chemokines,
adhesion molecules, and nitric oxide (NO) synthase (6).
As first line of defense to infection, the complement
cascade, neutrophils and endothelial cells are activated,
inducing the expression of adherence molecules on endothelial
cells and promoting neutrophil and subsequent monocyte
migration and extravasation to the site of inflammation.
Monocytes differentiate into macrophages in situ and secrete
a mixture of pro-inflammatory [e.g., tumor necrosis factor
(TNF)-α and interleukin (IL)-1] and anti-inflammatory
(e.g., IL-10) mediators. The ingestion of apoptotic neutrophils
by inflammatory macrophages induces their switch to
anti-inflammatory macrophages with repair properties (7).
These processes are responsible for the cardinal signs
of local inflammation: warmth and erythema due to local
vasodilation and hyperemia, protein-rich edema due to increased
microvascular permeability and pain due to mediators released
by innate immune cells.
A fine-tuned balance of pro-inflammatory and anti-
inflammatory mediators regulates and restricts the inflammatory
processes, the invading pathogens are cleared, homeostasis is
restored and tissue repaired. The systemic dissemination of
the immune response to uninfected remote tissue and failure
to restore homeostasis, leads to a malignant intravascular
inflammation called sepsis.
Sepsis is characterized by an aggravated, uncontrolled, and
self-sustaining inflammation which spreads via the circulation.
The exact mechanism by which an inflammation switches from
being locally restricted to systemically spread is unclear and is
likely to be multifactorial. Pathogens and their toxic products
contribute to this process, as endotoxins are found in the
blood of patients and associated with shock and multiple organ
dysfunction. The most common causes of sepsis are infections of
the respiratory system, followed by genitourinary and abdominal
infections (8). While sepsis can be caused by infection with
bacteria, virus and fungi, the most frequent pathogens in
sepsis are gram-positive bacteria such as Staphylococcus aureus
and Streptococcus pneumoniae (4, 9). However, almost half
of all patients with sepsis have unknown infections and are
pathogen culture negative. This form of sepsis is on the rise and
associated with higher incidences of acute organ dysfunction and
mortality (10).
Systemic Effects of Sepsis
The systemic immune response results in widespread cellular
injury, which precedes organ dysfunction. The precise
mechanism of cellular injury is highly complex and still
incompletely understood. The main mechanisms involved
include: cytopathic injury, which is mediated by direct cell
injury by pro-inflammatory mediators and/or other products of
inflammation, tissue ischemia due to insufficient oxygen supply,
and an altered rate of apoptosis.
Tissue ischemia is caused by endothelial and microcirculatory
lesions. Circulating inflammatory mediators activate the
endothelium and induce loosening of tight junctions between
endothelial cells, thereby increasing vascular permeability and
leakage. As a consequence, systemic endothelial activation leads
to hypotension and edema formation and thus to inadequate
tissue oxygenation (11). Moreover, erythrocytes lose their normal
ability to deform within the systemic microcirculation during
sepsis (12), which impedes microcirculatory blood flow and
depresses tissue oxygen supply. Microcirculatory lesions further
occur as a result of imbalances in the coagulation and fibrinolytic
systems, both of which are activated during sepsis.
Pro-inflammatory cytokines during sepsis promote cytopathic
injury and also delay apoptosis in activated macrophages and
neutrophils, thereby prolonging or augmenting the inflammatory
response and contributing to the development of multiple organ
failure. During the later phases of sepsis endotoxin tolerance (13)
and extensive lymphocyte and dendritic cell apoptosis alter the
immune response efficacy, decreasing the clearance of invading
microorganisms and increasing the susceptibility to secondary
infections (14).
Patients that die of sepsis show numerous overlapping
mechanisms of immunosuppression involving both innate and
adaptive immunity. Immune cells from spleens or lungs of
septic patients, harvested shortly after the patients died, display
a significant decrease in the production of pro- and/or anti-
inflammatory cytokines and upregulated expression of inhibitory
receptors including PD1. Also, the immunosuppressive cell
populations of regulatory T cells andmyeloid-derived suppressor
cells are increased and CD28 and HLA-DR-mediated activation
pathways downregulated (15).
During sepsis many cellular functions are affected, including
mitochondrial functions which results in altered metabolic
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substrate utilization, biogenesis and mitochondrial reactive
oxygen species (ROS) production. Reduced autophagy of
damaged mitochondria and autophagy exhaustion further
enhances inflammatory dysregulation and tissue injury (16).
Sepsis further promotes a pro-coagulant and pro-thrombotic
state of the host. Local and circulating endotoxins induce
the expression of tissue factor (TF) on endothelial cells
and monocytes, promoting intravascular fibrin deposition and
vascular occlusion. Moreover, microbial pathogens trigger the
release of neutrophil extracellular traps (NETs) from neutrophils
which provide a negatively charged surface for the activation
and assembly of coagulation factors (17). Activation of the
coagulation cascade provides a positive feedback loop inducing
platelet activation via generation of thrombin, thereby promoting
microthrombosis in response to inflammation and infection.
This so-called immunothrombosis is part of the anti-microbial
host response and aims to entrap invading pathogens and prevent
their spreading although this mechanism is likely pathogen- and
organ-dependent (18, 19). Further, the activated endothelium
increased the recruitment and adhesion of circulating platelets,
thus contributing to the formation of microthrombi throughout
the body (20). During sepsis platelets can be sequestrated in
the capillary-rich microvasculature of the spleen and liver.
However, the majority of platelets accumulate in the lung
microvasculature (21–23).
Thus, excessive responses of the immune system during
sepsis are often associated with exaggerated and dysregulated
activation of coagulation and thrombosis, manifesting itself
as disseminated intravascular coagulation (DIC). During DIC
microthrombi readily form within small and medium vessels,
leading to disturbed tissue oxygenation, multi-organ, and
eventually circulatory failure (24).
Activated platelets promote the development and progression
of sepsis via their involvement in inflammation and thrombosis.
Sepsis is characteristically accompanied by a drop in platelet
count, reflecting their sequestration and their consumption in
microthrombi although many other mechanisms contribute to
the severity and persistence of thrombocytopenia (see below)
(20). Severe thrombocytopenia is associated with a dysregulated
host response leading to an increase in cytokine levels and
endothelial dysfunction (25, 26). Hence, sepsis is associated
with increased systemic thrombosis and coagulation as well as
with elevated risk of hemorrhage due to the consumption of
coagulation factors and platelets (24). Thrombocytopenia was
found to correlate with sepsis disease severity and is associated
with increased mortality risk (27, 28).
Organ Specific Effects of Sepsis
Overwhelming systemic inflammation results in organ
dysfunction. While no organ is protected from the consequences
of sepsis, the most common complications are outlined below.
Circulation
During sepsis vasoactive mediators, including prostacyclin and
NO, are released by endothelial cells. NO synthase can be
induced by endotoxin and NO plays a central role in the
vasodilation accompanying septic shock (29). Systemic NO
release results in persistent vasodilation and diminishes the
response to vasoconstrictors during sepsis (29). Furthermore,
compensatory secretion of antidiuretic vasopressin is diminished
during sepsis.
In the central circulation, decreased systolic and diastolic
pressure diminishes the cardiac output. Low blood pressure
also leads to disturbed blood flow in small vessels and restricts
capillary functions in the microcirculation, leading to inefficient
oxygen extraction due to edema, endothelial swelling and
plugging by leukocytes.
Sepsis leads to endothelial dysfunction via direct and indirect
interactions with pathogens. Degradation of the endothelial
glycocalyx is associated with the upregulation of adhesion
molecules (30), promoting the adherence of blood cells, which
fosters mutual activation and further promotes inflammation and
edema formation.
Gastrointestinal Tract
Hemodynamic abnormalities during sepsis depress the normal
barrier function of the gut, allowing translocation of microbiota
into the systemic circulation, further contributing to the
progression of sepsis (31).
Lung
During sepsis microbial burden and/or increased inflammation
results in endothelial injury of the pulmonary vasculature,
leading to edema, increased leukocyte influx, and diminished
oxygen supply. Excessive infiltration of innate leukocytes
amplifies these processes by boosting inflammatory responses,
causing injury to the lung tissue and hemorrhage, and thus causes
loss of lung function. This may lead to the acute respiratory
distress syndrome characterized by loss of the alveolar-capillary
barrier function and increased vascular permeability, lung injury,
and pulmonary edema (32). Clinical presentation thus includes
diffuse bilateral pulmonary infiltrations and acute and persistent
arterial hypoxia.
Liver
The liver works as a lymphoid organ in response to sepsis by
mediating immune responses, leading to clearing of bacteria
and toxins but also causing inflammation, immunosuppression,
and organ damage. Attenuating liver injury and restoring liver
function lowers morbidity and mortality rates in patients with
sepsis (33).
Kidney
Acute kidney injury is a common phenomenon in sepsis and
occurs in 40–50% of septic patients and increases mortality by
6–8-fold (34). The underlying mechanism is still incompletely
understood. While previous notions regarded organ dysfunction
solely as side effect of hypoperfusion, recent studies challenge
this view and emphasize a role of heterogeneous areas of
colocalized sluggish peritubular blood flow and tubular epithelial
cell oxidative stress. Microvascular dysfunction, inflammation,
and the metabolic response to inflammatory injury are crucial for
the pathophysiologic mechanisms of kidney damage (34).
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Brain
Sepsis is often characterized by an acute brain dysfunction
which is associated with increased morbidity and mortality. Its
pathophysiology is highly complex and involves inflammatory
and non-inflammatory processes. Pathophysiological
mechanisms include excessive microglial activation, impaired
cerebral perfusion, blood-brain-barrier dysfunction, and
altered neurotransmission. Systemic insults, such as prolonged
inflammation, severe hypoxemia, and persistent hyperglycemia,
may also contribute to aggravate sepsis-induced brain
dysfunction or injury (35).
PLATELETS IN SEPSIS
Sepsis is characteristically accompanied by increased activation
of platelets, small anucleate blood cells with pivotal functions in
hemostasis. It is becoming increasingly apparent that platelets
have also essential roles in immunity and modulate physiologic
and pathologic responses to inflammation and infection.
Platelets are crucial regulators of leukocyte function and thus
of inflammatory immune responses (36). They readily interact
with innate immune cells and exert immunomodulatory effects
directly via cell-cell contact or indirectly via the release of
chemokines and cytokines (37). Platelets promote endothelial
adhesion and extravasation of leukocytes at sites of inflammation
while securing vascular integrity at the site of transmigration.
They modulate cytotoxic neutrophil effector function and induce
a pro-inflammatory phenotype of neutrophils by modulating
their activation, phagocytosis, oxidative burst, and formation of
NETs. Platelets are also involved in monocyte differentiation
into macrophages and modulate their effector functions.
Thereby platelets also contribute to excessive inflammatory
host response during sepsis and promote the development and
progression of sepsis via their involvement in both inflammation
and thrombosis. On the other hand, platelets can inhibit
inflammation and promote tissue repair in a receptor- and organ-
dependent manner. Therefore, the balance between the pro-
inflammatory and anti-inflammatory roles of platelets regulates
the outcome.
Platelet Receptors in Sepsis
Platelets express various receptors that are involved in the
initiation and progression of sepsis. They include receptors
for pathogen recognition, immune cell activation and platelet
activation. While a plethora of receptors are ubiquitously
expressed on platelets, others are only found on platelet
subpopulations [e.g., TLRs (38)]. Circulating platelets
differ in age, maturation state, or density. It is currently
unknown if receptor composition differs due to platelet
maturation, differences in thrombopoiesis and receptor
distribution during platelet formation (39) or if a subset of
megakaryocytes produces immune-regulatory platelets which
express e.g., TLRs, while others produce platelets that only
fulfill thrombotic functions. Moreover, there are gender-
specific differences in expression levels of some receptors.
Women, for example, express more copy numbers of TLRs
compared to men (40) and receptor expression correlates
FIGURE 1 | The role of platelets in sepsis and receptors involved in mice and
humans. Human and mouse platelets express a variety of immune receptors
involved in thrombosis or/and inflammation during sepsis. Many receptors are
conserved between mice and human and other receptors are
species-restricted. FcαR, Fc-alpha receptor; FcεR, Fc-epsilon receptor; FcγR,
Fc-gamma receptor; TLR, toll-like receptor; CLEC-2, C-type lectin-like
receptor-2; DC-SIGN, dendritic cell-specific intercellular adhesion
molecule-3-grabbing non-integrin; NOD, nucleotide binding oligomerization
domain containing 1; GP, glycoprotein; P2Y12, purinergic receptor P2Y12;
PAR, proteinase-activated receptor.
with distinct cardiovascular risk and inflammatory biomarkers
(40). Interspecies differences in receptor expression and
copy numbers are even bigger. Mice and humans not only
strongly differ in platelet count but also show differences in
receptor density and co-receptor expression (41–43). Moreover,
some receptors are not expressed in mice, while they fulfill
important immunomodulatory functions in humans (e.g.,
FcγRIIA). This makes it often difficult to translate results
from animal models to the clinical situation. A comparison of
human and murine receptors relevant to sepsis pathology is
given in Figure 1.
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Toll-Like Receptors (TLRs)
TLRs are type I transmembrane proteins comprising of an
ectodomain, which contains leucine-rich repeats that mediate the
recognition of PAMPs, a transmembrane region, and a cytosolic
Toll-IL-1 receptor (TIR) domain that activates downstream
signaling pathways. TLRs are either expressed on the cell surface
or associated with intracellular vesicles. Each TLR detects distinct
PAMPs and therefore recognizes viruses, bacteria, mycobacteria,
fungi, or parasites (44).
Human and murine platelets express functional TLRs.
TLR2 regulates megakaryopoiesis (45), thromboinflammation
(46), and bacterial phagocytosis (47). TLR7 stimulation
triggers platelet degranulation and platelet-leukocyte aggregate
formation and alters survival in virally infected mice (48).
TLR9 regulates foreign DNA sequestration and CD62P surface
expression in platelets (49). TLR4 is involved in rapid TNF-α
induction (38), NET formation (50), and thrombocytopenia
(38, 51). During gram-negative infection but not gram-
positive infection, TLR4 activation induces the expression
of neuraminidase, promoting alkaline phosphatase clearance
and increasing LPS phosphorylation and toxicity (52–54).
Interestingly, injection of neuraminidase post Streptococcus
pneumoniae infection promotes survival and decreases fibrin
clot frequency as well as liver and spleen injury in septic mice.
Neuraminidase further induces moderate thrombocytopenia
with platelet counts dropping by 70%, indicating that moderate
thrombocytopenia might be beneficial in sepsis (55).
While TLR2 is only expressed on a small subset of platelets
(10–20%), TLR4 is found on approximately 60% of human and
40% of murine platelets (23, 38). TLR9 is found on approximately
40% of resting human platelets and can increase to up to 60%
in activated platelets indicating an intracellular storage pool of
TLR9 (38, 49, 56). In mice, 60% of platelets are TLR9 positive and
no further upregulation could be observed upon activation (38).
C-Tlatelet Antibodype Lectin Receptors (CLRs)
CLRs comprise a large family of receptors that bind to
conserved bacterial structures via carbohydrate-recognition
domains (CRDs) in a calcium-dependent manner. Based on their
molecular structure, two groups of membrane-bound CLRs can
be distinguished. Type I CLRs carry multiple CRDs or CRD-
like domains, while Type II CLRs contain only a single CRD.
CLRs are expressed on several immune cells. On platelets CD23
(FcεRII) and dendritic cell-specific ICAM-grabbing non-integrin
(DC-SIGN) are expressed and functional (57–60). DC-SIGN is
involved in lentiviral internalization by platelets (57).
Nucleotide-Binding Oligomerization Domain-Like
Receptors (NOD-Like Receptors)
NOD-like receptors are cytoplasmic receptors with a strong
structural similarity. All NOD-like receptors contain a
central nucleotide-binding oligomerization domain (NOD),
a C-terminal leucine-rich repeat domain and a variable
N-terminal protein-protein interaction domain which interacts
with downstream effectors. NOD1 and NOD2 are the two
important NOD-like receptors fitting the typical structure with
NOD1 containing one caspase recruitment domain (CARD),
whereas NOD2 contains two CARD domains (61). While NOD1
recognizes d-glutamyl-meso-diaminopimelic acid primarily
from gram-negative bacteria, NOD2 detects the muramyl
dipeptide (MDP) motif in peptidoglycan from all bacteria.
NOD1 is broadly distributed, whereas NOD2 is mainly expressed
in innate immune cells (61) and platelets (62). In platelets NOD2
contributes to platelet activation and is possibly involved in
arterial thrombosis during infection (62).
Glycoprotein Ib (GPIb)
GPIb is exclusively expressed on platelets and megakaryocytes
and plays a crucial role in platelet adhesion under high shear.
GPIb is part of the GPIb-V-IX complex, which binds von
Willebrand factor (vWF), allowing platelet adhesion and platelet
plug formation at sites of vascular injury. Many bacteria such
as Streptococcus sanguis contain serine-rich protein A (SrpA)
which is also recognized by GPIb and allows platelet-bacteria
binding in a sialic acid-dependent manner (63). Staphylococcus
aureus protein A (Spa) also binds vWF, which mediates indirect
interaction with platelets via GPIb (64).
Integrin αIIbβ3 (GPIIb/IIIa)
Glycoprotein IIb/IIIa (GPIIb/IIIa) represents the most abundant
platelet glycoprotein and is central for platelet aggregation via
fibrinogen bridging. GPIIb/IIIa becomes activated via inside-
out signaling, leading to a conformational change that uncovers
an arginine-glycine-aspartic acid (RGD) sequence, allowing the
binding of fibrinogen, vWF, fibronectin and vitronectin, and
platelet aggregation (65). Several bacterial proteins are able to
bind to the RGD sequence on GPIIb/IIIa, including SdrG (Fbe)
from Staphylococcus epidermis causing platelet aggregation (66).
Borrelia burgdorferi also binds human platelets via GPIIb/IIIa
(67). Clumping factors (Clf) on Staphylococcus aureus bind
fibrinogen causing platelet aggregation (68).
Glycoprotein VI (GPVI)
GPVI is an immunoreceptor tyrosine-based activation motif
(ITAM) receptor that plays a crucial role in the collagen-induced
activation and aggregation of platelets. By binding to exposed
subendothelial collagen, GPVI mediates the sealing of vascular
injuries and ensures integrity of the circulatory system.
Protease Activating Receptors (PARs)
PARs are a subfamily of related G protein-coupled receptors
highly expressed on platelets and are activated by cleavage
of part of their extracellular domain by thrombin. Human
platelets express PAR-1 and PAR-4 with PAR-1 mediating
strong thrombin-induced activation. In contrast, murine platelets
express PAR-3 and PAR-4 (69) with PAR-4 being the most potent
receptor for thrombin.
Fc Receptors
Human platelets are reported to express various Fc receptors
including FcαRI (CD89) (70), FcεRI (71), FcεRII (CD23) (59),
and FcγRIIA (CD32a) (72). In infectious settings, FcγRIIA
mediates immune complex-induced platelet activation or killing
of opsonized bacteria (73, 74).
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P2Y Receptors
P2Y receptors are a family of purinergic G protein-coupled
receptors, stimulated by nucleotides such as adenosine
diphosphate (ADP). The ADP receptors, P2Y1 and P2Y12,
are differentially involved in pro-thrombotic platelet activation
as well as expression of platelet P-selectin in response to various
agonists (75). P2Y12 inhibitors are routinely used in the clinics
for prevention of thrombotic complications.
P-Selectin (CD62P)
In resting platelets, CD62P is stored in the α-granule membrane
and becomes exposed on the platelet surface upon activation.
CD62P functions as adhesion molecule and is responsible
for platelet interaction with activated endothelial cells and
leukocytes via binding to its ligand P-selectin glycoprotein
ligand 1 (PSGL-1), which enables platelets to fine-tune their
cellular functions.
CD40 Ligand (CD40L)
Following activation platelets upregulate CD40L, promoting
their interaction with innate immune cells, in particular
monocytes. CD40L can be shed by metalloproteinase 9 (MMP9)
which is upregulated during sepsis, resulting in a significant
increase in soluble CD40L.
Platelet Activation in Septic Patients
Increased platelet activation is observed in septic patients and
is further potentiated in septic shock. Platelet activation is
associated with the upregulation of surface expression of CD62P,
CD63, CD31, increased fibrinogen binding and soluble GPVI
(76–79), particularly in patients with DIC (80). Moreover, an
increase in thrombospondin expression on circulating platelets
is observed in patients with multiple organ failure (77).
Platelets from septic patients show spontaneous aggregation but
the ex vivo response to platelet agonists is severely reduced
(81–83). Interestingly, the impairment in platelet aggregation
is not associated with DIC (82). Whereas, platelet activation
in sepsis is not questioned, platelet aggregation data is more
contradictory due to the low platelet count in these patients
which is not taken into account in many studies (80). Platelet
activation is also associated with increased platelet-neutrophil
and platelet-monocyte aggregates in septic patients (84, 85)
further potentiating the inflammatory response. Together these
results suggest that septic patients’ platelets circulate in an
activated state, increasing their thrombotic potential (84).
Different mechanisms may contribute to direct and indirect
platelet activation during sepsis, including platelet activation
by the pathogen (86–90), pathogen- and inflammation-driven
activation of the endothelium and leukocytes and complement
activation-mediated platelet activation (91). The complexity
of platelet activation in sepsis suggests the contribution of
multiple receptors, making it likely that combined therapy might
be required to inhibit platelet activation in sepsis. However,
increased bleeding risk in these patients adds another layer of
complexity for targeting platelets in septic patients.
Platelet Count in Septic Patients
The correlation between platelet count and sepsis severity and
outcome has drawn increasing attention to the contribution of
platelets to the pathophysiology of sepsis (92, 93). The critical
role of platelets in sepsis is emphasized by the fact that platelet
count is included in the SOFA score and is inversely associated
with sepsis severity (94). Thrombocytopenia is often used to
stratify patients with sepsis and septic shock based on the nadir of
platelet count: mild thrombocytopenia (platelet count< 100–150
× 109/L), moderate thrombocytopenia (platelet count between
50 and 100× 109/L) and severe thrombocytopenia (platelet count
< 50× 109/L), with severe thrombocytopenia being associated
with worse outcomes (25). Another important parameter is
relative thrombocytopenia, that represents a drop of the initial
platelet count over 4 days (95). Indeed, the kinetics of platelets
in sepsis is often biphasic, characterized by an initial drop
within the first few days (day 1–4) followed by an increase in
platelets and thrombocytosis (96). Lack of this biphasic response
leads to persistent thrombocytopenia and is associated with poor
prognosis and increased 28-day mortality (96, 97).
Thrombocytopenia may occur before admission at the
hospital or during the ICU hospitalization (96, 98, 99). Of
note, a single measurement of platelet count is not predictive
of mortality (92, 96, 100). The initial platelet drop does not
discriminate between survivors and non-survivors while late
thrombocytopenia is more predictive for mortality. Indeed,
stratification of septic patients revealed that not only the
severity of thrombocytopenia but more importantly persistence
of thrombocytopenia is associated with worse outcome. Severe
thrombocytopenia is independently associated with disease
severity and mortality at the ICU admission and is associated
with a dysregulated host response (25).
In general, 20–58% of septic patients develop
thrombocytopenia, of which 10% develop severe
thrombocytopenia (28, 93, 96, 98, 101). The discrepancy in
the reported values might arise from patient heterogeneity,
different inclusion criteria, pathogens and other factors.
Moreover, a decrease in immature platelets, indicating impeded
thrombopoiesis, is associated with severe thrombocytopenia and
28-day mortality (102). One recent study showed that immature
platelet fractions could predict sepsis occurrence in critically
ill subjects (103). Interestingly, phosphatidylserine-expressing
platelet microvesicles are decreased in non-survivors and
correlate with thrombocytopenia but are not associated with DIC
(104). Therefore, severity and persistence of thrombocytopenia
as well as immature platelet fractions and platelet microvesicle
composition are strong predictors of mortality in sepsis.
Causes of Thrombocytopenia in Septic
Patients
The association between thrombocytopenia and clinical outcome
does not reveal any causality as many parameters could be both
the cause and/or the consequence of dropping platelet counts.
Thrombocytopenia can either occur due to diminished
platelet production or increased platelet turnover. Platelet
activation diminishes platelet life span as activated platelets are
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rapidly cleared from the circulation. Animal models revealed that
thrombocytopenia in sepsis is largely TLR4-dependent, which
suggests that immune-mediated platelet activation represents a
main cause for the drop in platelet count (38). Many mechanisms
have been proposed for thrombocytopenia in sepsis although a
combination of multiple mechanisms might occur in severely
thrombocytopenic patients. An overview of these processes is
given in Figure 2.
Platelet-Leukocyte Aggregation
The formation of platelet-leucocyte aggregates (PLA) in the
blood depends on platelet activation and is an early phenomenon
occurring in sepsis. Circulating PLA are increased in sepsis
patients at an early phase, but significantly decrease in non-
survivors and patients developing multiple organ failure, likely
due to enhanced peripheral sequestration or sepsis-associated
thrombocytopenia (84). Platelet-neutrophil aggregates can also
potentiate thrombocytopenia through the release of platelet-
activating NETs (105).
Pathogen-Induced Thrombocytopenia
Fungi and bacteria can interact with platelets and induce
platelet activation and aggregation (86, 87, 89). Although
many bacteria activate platelets in a GPIIb/IIIa- or FcγRIIA-
dependent manner and involve plasma proteins such as IgG,
complement proteins and fibrinogen, other bacteria directly
bind and activate platelet receptors such as GPVI and TLRs,
increasing platelet activation and PLA formation (46, 87,
106). Mechanisms of pathogen clearance by platelets may
occur indirectly through the release of various antimicrobial
peptides and platelet-derived mediators regulating the activation
of the endothelium and immune cells. Some pathogenic
bacteria, particularly blood stream infections, may also trigger
apoptosis in platelets resulting in thrombocytopenia (107,
108). Thrombocytopenia occurs in 20–30% of patients infected
with Staphylococcus aureus, Escherichia coli, or Streptococcus
pneumonia, suggesting that platelet activation by pathogens
contributes to thrombocytopenia but does not represent a major
mechanism (109). TLR4-mediated responses reduce platelet
counts in murine endotoxemia (38, 110), but the role of TLR4
in patients has never been investigated.
Tissue Injury-Mediated Platelet Activation
Infections are commonly associated with tissue injury and cell
destruction that fuel inflammation. DAMPS and other mediators
released from activated and injured cells such as histones
and high mobility group protein B1 (HMGB1) can activate
platelets and enhance agonist-induced platelet activation and
granule secretion, potentiating thrombocytopenia and delaying
its resolution (111–113).
Clearance Through Desialylation
Platelet desialylation is increased in septic patients
with thrombocytopenia compared to patients without
thrombocytopenia (114). Desialylation occurs during
pneumococcal infections, leading to the release of neuraminidase
and the exposure of galactose residues, increasing the clearance
of platelets by the Ashwell Morrell receptors (AMR) on
hepatocytes. GPIbα is the main receptor involved in platelet
clearance and is desialylated by neuraminidase, although other
glycoproteins are also susceptible to desialylation. Moreover,
platelet desialylation increases platelet reactivity, thereby
potentiating thrombocytopenia (115).
Anti-platelet Antibodies
Another possible mechanism that contributes to
thrombocytopenia is the immune clearance and destruction of
platelets. Anti-platelet antibodies (e.g., anti-PF4/heparin) are
detected in patients with bacterial septicemia and their level
increases in thrombocytopenic patients with no significant
difference between gram-positive and gram-negative infection
(116–118). Moreover, IgG-opsonization enhances the clearance
of LPS-binding platelets in an Fc-dependent manner and further
potentiates platelet clearance in gram-negative infection (51).
Inflammation fosters immune thrombocytopenia as C-reactive
protein, produced during the acute phase of inflammation,
enhances antibody-mediated platelet clearance by FcγR-
dependent phagocytosis (108). More recently a novel mechanism
of platelet sequestration through FcγRIIA activation by immune
complexes was suggested (119). These studies consolidate that
different mechanisms contribute to thrombocytopenia during
different infections.
Disseminated Intravascular Coagulation (DIC)
DIC is defined as an excessive fibrin deposition leading to the
occlusion of blood vessels and organ damage that is associated
with consumption of coagulation factors and platelets. DIC is
often associated with low platelet count, abnormal coagulation
and fragmented cells; however thrombocytopenia is not always
associated with DIC (100). DIC was one of the first mechanisms
suggested to explain thrombocytopenia in septic patients but the
low association between thrombocytopenia and DIC (15–30% of
patients with thrombocytopenia present with DIC) suggests that
DICmight contribute to thrombocytopenia only in some cases of
severely ill patients (96, 120). DIC is mostly observed in patients
with septic shock, however the association between DIC and
mortality largely depends on the study and the inclusion criteria
(96). More recently, it was shown that although DIC occurs in
septic patients and mice, the time course and the composition
of thrombi differ between organs even within the same infection
(18, 121). This might be due to the different susceptibility of the
endothelium, the local and systemic generation of coagulation
factors, fibrinolytic factors and extracellular matrix proteins as
well as due to the activation of immune cells.
Platelet Production (Thrombopoiesis)
The presence of normal megakaryocyte counts in the bone
marrow of septic patients with low platelet count suggests
that thrombopoiesis remains unaffected (95). Moreover, the
increase in immature platelet fraction, the absolute immature
platelet count and the increase in thrombopoietin (TPO) levels
consolidate this hypothesis (122, 123). Increased TPO levels
might result from reduced platelet count or enhanced TPO
production in the liver by inflammatory mediators. However, in
some severely ill patients with advanced thrombocytopenia, a
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FIGURE 2 | Possible causes of thrombocytopenia in sepsis. Thrombocytopenia in sepsis might be either regulated by altered platelet production or
hemophagocytosis, or by platelet scavenging in the circulation either due to platelet-leukocyte or platelet- pathogen interactions, vessel injury, or desialylation.
Platelets can also be targeted by antibodies during sepsis or reduced due to disseminated intravascular coagulation (DIC).
defect in thrombopoiesis might occur, which could explain why
these patients do not recover to a normal platelet count (102).
Cytokine-Driven Hemophagocytosis
An increase in the proliferation and activation of monocytes
and macrophages in the bone marrow was observed in
septic patients with thrombocytopenia. The uncontrolled
proliferation is associated with an increase in macrophage-
colony stimulating factor (M-CSF) which accelerates the
ingestion of hematopoietic cells by macrophages and may
contribute to thrombocytopenia (124).
Taken together, mild and moderate thrombocytopenia might
result from one or the combination of different mechanisms,
whereas severe and non-resolved thrombocytopenia involves
concomitant mechanisms of platelet activation, sequestration
and destruction.
Anti-platelet Drugs in Sepsis
Several observational and retrospective clinical studies have
shown that anti-platelet agents such as aspirin (COX-1
inhibitor), platelet P2Y12 receptor antagonists like clopidogrel
or GPIIb/IIIa antagonists reduce mortality or complications in
critically ill patients (99, 125, 126). In human experimental
endotoxemia, P2Y12 inhibitors reduce the pro-inflammatory and
pro-thromboticmechanisms (127). Further, in septic patients low
dose aspirin is associated with a decrease in mortality during
hospitalization (128). Patients on low dose aspirin have shorter
in-hospital stays and reduced need for intensive care treatment.
Administration of aspirin for 24 h at the time of SIRS recognition
is associated with increased survival in a large cohort of over
5,000 septic patients (129).
Inhibition of platelet function in sepsis represents an attractive
target due to their role in thrombosis and inflammation.
However, as platelet receptors play different roles in thrombosis,
inflammatory hemostasis and inflammation, precautions have
to be taken when targeting platelets in infection (130). Large
randomized controlled clinical trials with anti-platelet therapy
in stratified patients are warranted to determine a conclusive
beneficial effect of anti-platelet drugs in sepsis.
RODENT MODELS TO STUDY THE ROLE
OF PLATELETS IN SEPSIS
In septic patients, disease progression before hospital admission
often remains unknown. Therefore, it can be challenging
to determine cause and effect of the clinical symptoms.
Animal models help to unravel these early processes and the
availability of genetically modified mouse strains contributed
to the identification of distinct signaling pathways or genes as
potential biomarkers or drug targets. Thus, rodent and especially
mouse models have proven to be convenient and widely-used
tools to study cellular and molecular mechanisms of sepsis in
defined settings.
A number of different sepsis models have been developed
that vary in technical complexity, controllability, and
representativeness for the human sepsis patient setting. As
sepsis commonly originates from infections of lung and
genitourinary tract and to a less extend the abdomen (8),
intraperitoneal or pulmonary routes are favored for primary
induction and experimentally easy accessible. An overview of the
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different animal models used to investigate the role of platelets
and their receptors in sepsis is given in Figure 3.
Different Models to Study Platelet Function
in Sepsis
Single PAMP
The most controllable in vivo model is the injection of a single
bacterial or fungal PAMP via intravenous, intraperitoneal,
or intranasal/intratracheal application. Most commonly LPS
from gram-negative Escherichia coli or Klebsiella is used,
which stimulates TLR4 on host cells including platelets
(23). LPS represents a weak platelet agonist and primes
platelets for stimulation with other agonists (131), though
its effect on platelet degranulation may not be detectable
in every experimental setting (23). LPS usually signals via
MyD88, however lack of platelet MyD88 did not alter host
responses to LPS including thrombocytopenia and immune
cell recruitment (132). Intravenous challenge with low-
dose (0.125–0.25 mg/kg) LPS leads to rapid but transient
thrombocytopenia accompanied by platelet sequestration
in capillary-rich organs such as lungs and liver (133). For
intraperitoneal application doses commonly range between 1
and 10 mg/kg which induces prolonged thrombocytopenia,
platelet sequestration and innate immune cell infiltration
into lungs and liver, changes in the coagulation state and an
inflammatory cytokine response involving TNF-α and IL-6,
which may eventually lead to death (23, 134). As such, LPS
triggers a strong but short-lived response favoring the innate
immune system.
However, the intensity of platelet responses depends on
the specific LPS serotype of the O antigen, the outermost
polysaccharide domain of the molecule. LPS serotypes O8 and
O9 readily induce platelet activation, thrombocytopenia, platelet
sequestration in the lungs and liver as well as increased mortality,
whereas O111 and LPS of the strain K-12, lacking an O
antigen, trigger weaker responses (135). Additionally, LPS can be
classified in smooth (full-length O chains) or rough (reduced or
absent O chains). A comparison of eight different smooth and
rough LPS serotypes from Escherichia coli, Klebsiella, Salmonella
minnesota, and Salmonella typhimurium in mice identified LPS
of Klebsiella O3 as most potent to induce a platelet response and
shock, triggering a complement-dependent accumulation and
degradation of platelets in lungs and liver (136).
In addition to LPS administration, cell-surface proteins from
gram-positive bacteria such as the M1 protein of Streptococcus
pyogenes can be used to mimic sepsis that does not engage TLR4,
but rather stimulates the immune system via super-antigens or
peptidoglycans (137). However, M1-induced sepsis represents an
unfavorable model to study platelets in sepsis as M1 challenge
leads to neutrophil-dependent organ damage independently of
platelets (138).
Fungal sepsis can be investigated by injection of the yeast-
derived cell surface glucan zymosan A (e.g., from Saccharomyces
cerevisiae) which activates TLR2 and the alternative complement
pathway. Unlike LPS, zymosan A induces a triphasic immune
response which resembles the prolonged sepsis in humans.
The first phase is characterized by a strong pro-inflammatory
response with high levels of TNF-α and IL-6, followed by chronic
low-grade inflammation which eventually culminates in organ
damage and death (137, 139).
Nevertheless, screening of literature revealed that LPS from
Escherichia coli O111:B8 appears to be the most commonly used
agent for murine endotoxemia.
Single Live Pathogen
Injection of a single, live pathogen is more representative of
infections in patients that originate from one infectious agent.
While, by nature of live pathogens and their proliferation
in vivo, this model has a lower level of controllability than
injection of isolated PAMPs, the possibility of challenging
animals with individual pathogens of choice provides the huge
advantage of studyingmechanisms underlying specific pathogens
or bacterial strains.
Commonly used bacteria to study the role of platelets
in murine sepsis models include Escherichia coli, Klebsiella
pneumoniae, Staphylococcus aureus, Streptococcus pyogenes, and
Streptococcus pneumoniae (140–144). Although intravenous
injection of bacteria leads to strong bacteremia, complement-
mediated host responses may prevent efficient colonization of
organs and as such this model fails to accurately reproduce
human sepsis (145). Additionally, due to the immediate effect on
endothelial cells and the vasculature, intravenous administration
triggers a potent, rapid, pro-inflammatory immune response
that may be stronger than the host response induced by a
local infection.
Nonetheless, challenge with single live pathogens represents
a good model to study e.g., pneumosepsis, in which infections
originate in the lungs before spreading systemically. Accordingly,
intranasal infection with 104-106 colony forming units (CFU)
of Klebsiella pneumoniae or Streptococcus pneumoniae, the most
common gram-negative and gram-positive causative pathogens
of community-acquired pneumonia, respectively (146), induces
local pulmonary inflammation with accompanied cytokine
response and infiltration of neutrophils and macrophages into
the inflamed lungs. As local immunity becomes unable to contain
the infection, bacteria disseminate into the bloodstream and
can be detected in distant organs such as spleen, kidneys,
and liver (141, 144).
Therefore, infection with live bacteria also allows studying of
antibacterial host responses including phagocytosis, formation of
NETs and release of antimicrobial agents, which play important
roles in human sepsis.
In addition to live bacteria, experimental sepsis can also be
induced by the human commensal fungus Candida albicans
which may cause sepsis in humans upon breaching mucosal
barriers of the gut e.g., following surgery or trauma (147). Innate
immune recognition of Candida albicans involves various CLRs
and TLRs, several of which are expressed on platelets (148).
Infection of susceptible mice with live Candida albicans results
in thrombocytopenia and decreased clotting times, indicating
activation of primary and secondary hemostasis similar to
bacterial sepsis (149).
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FIGURE 3 | Overview of different mouse models to study sepsis. The role of platelets was addressed using single PAMP injection, single live pathogen or
polymicrobial pathogens. Platelets regulate thrombosis, inflammation, bleeding, and sepsis outcome in a receptor- and pathogen-dependent manner. PAMP,
pathogen-associated molecular pattern; LPS, lipopolysaccharides; M1, streptococcal M1 protein; iv, intravenous; in, intranasal; ip, intraperitoneal; P2Y12, purinergic
receptor P2Y12; GP, glycoprotein; TLR, toll-like receptor; CLEC-2, C-type lectin-like receptor-2; PAR, proteinase-activated receptor.
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Polymicrobial Infection
Models of polymicrobial infection most closely resemble human
sepsis originating from an intestinal center of infection.
Cecal ligation and puncture (CLP) represents one of the
most commonly used sepsis models as it most closely resembles
sepsis in humans regarding biochemical, hemodynamic
and immune responses, including hypotension, leukopenia,
thrombocytopenia with a concomitant pro-thrombotic and
pro-coagulatory phenotype, raised levels of pro-inflammatory
cytokines as well as markers of organ dysfunction (150–152).
Perforation of the cecum mimics a breach of intestinal barrier
with subsequent dissemination of intestinal microbial flora
into the peritoneum. In CLP this peritonitis is combined
with necrosis of the ligated tissue and eventual dissemination
into the periphery, resulting in septicemia and distant organ
damage (152).
In addition to resembling the human sepsis situation, CLP
has the advantage of being adjustable in severity based on
the ratio of ligated tissue and the size and number of cecal
perforations. However, CLP is prone to variation due to the
operator and local immune responses may manage to contain
bacteria in an abscess, thereby preventing the progression to
septic shock (153). CLP-induced microvascular dysfunctions are
not mediated by LPS (154), underlining the importance of gram-
positive bacteria in this model. Compared to LPS challenge, the
inflammatory cytokine response to CLP develops slower, even at
similar mortality and morbidity (155), which may be due to the
gradual disease progression.
Another model of polymicrobial sepsis is the cecal slurry
(CS) method which comprises the intraperitoneal injection of a
defined amount of donor feces and results in a stronger early
inflammatory response than CLP (156). Curtailed variability in
infectious dose and technical ease make CS a suitable model for
polymicrobial infection in settings where surgery is problematic.
Underlying Mechanisms Identified by
Mouse Models
The Impact of Platelet Depletion on Sepsis
Platelet depletion has detrimental effects on survival in
gram-negative (Klebsiella pneumoniae) and gram-positive
(Streptococcus pneumoniae) pneumosepsis, accompanied by
increased pulmonary hemorrhage and clinical pathology score
(141, 144, 157). While pulmonary neutrophil infiltration appears
largely platelet-independent in live bacterial models, platelets
facilitate leukocyte recruitment in LPS/zymosan-induced lung
injury (158). Accordingly, platelets seem to contribute to
tissue injury in the absence of live pathogens. In contrast,
low platelet counts are associated with increased secondary
hemostasis, liver and kidney damage as well as exacerbated
bacteremia and systemic bacterial dissemination in bacteria-
induced sepsis (140, 141, 144, 158, 159). In line with these
findings, thrombocytopenia also exacerbates the inflammatory
response in sepsis, raising plasma levels of TNF-α, IL-6, IL-10,
myeloperoxidase (MPO), monocyte chemotactic protein 1
(MCP-1), and interferon-γ (IFN-γ) (141, 144, 159), potentially
as a consequence of more severe infection.
Nonetheless, the role of platelets in sepsis is multi-faceted
and current research has only begun to untangle the complex
interplay of inflammation, thrombosis, and coagulation that
occurs during sepsis. Indeed, the role of platelets may depend
on the specific pathologic setting and thus experimental
model, as platelet depletion in Streptococcus pyogenes actually
ameliorates weight loss, decreases bacterial burden and dampens
the inflammatory host response (143). The reason for this
discrepancy with other reports is currently unknown.
Platelets Receptors in Sepsis
Platelet receptors regulate platelet activation as well as
subsequent platelet-mediated modulation of immune responses
during sepsis.
Platelet TLR4 mediates microvascular thrombosis and
thrombocytopenia in response to LPS, thereby fostering tissue
injury caused by vessel occlusion. Furthermore, in Escherichia
coli infection platelet TLR4 contributes to bacterial trapping by
supporting NET formation (38, 50, 110).
Additionally, platelet activation during sepsis may be induced
by activation of secondary hemostasis with generation of
thrombin or release of vWF from activated endothelial cells,
respectively. Inhibition of PARs does not alter mortality,
inflammation, or thrombocytopenia in endotoxemic mice,
suggesting that thrombin formation is not the main cause
of thrombocytopenia in this model (160). Contrarily, in
Streptococcus pneumoniae-induced pneumosepsis PAR-4 limits
bacterial growth and lung damage (161).
Direct cellular interactions of activated platelets with
leukocytes or endothelial cells via surface expressed CD62P or
CD40L contribute to the inflammatory host response in sepsis,
fostering both bacterial clearance and organ damage (162–164).
Elevated CD62P promotes formation of platelet-neutrophil
aggregates in the circulation of septic mice, assisting pulmonary
neutrophil infiltration independent of local chemokines, and
thereby limiting bacterial dissemination but also contributing to
lung damage in pneumosepsis or CLP (162, 163, 165). Reduced
surface CD40L curtails direct platelet-leukocyte interaction and
dampens neutrophil infiltration and tissue damage in bacterial
sepsis (164).
Following LPS challenge, thrombocytopenia, thrombosis and
mortality are decreased in IL-4R/Ibα mice that lack the
extracellular part of GPIbα (166), showing a detrimental role
of GPIbα in endotoxemia. The role of GPIbα involves its
interaction with vWF as disruption of this axis confers the
same protective effect (166). While platelets commonly have
pro-inflammatory effects on leukocytes, GPIb seems to confer
anti-inflammatory leukocyte modulation as it supports platelet-
leukocyte interaction, but dampens the inflammatory cyto-
/chemokine response (167).
Furthermore, blockade of GPIIb/IIIa using integrilin also
reduces mortality but did not alter thrombocytopenia in LPS-
challenged mice (166), suggesting that thrombocytopenia is not
the main cause of mortality in this model.
Recent studies have also identified glycoprotein GPVI and
CLEC-2 as novel modulators of inflammatory responses in gram-
negative sepsis or CLP. GPVI contributes to local immunity
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in pneumosepsis by enhancing platelet-neutrophil-aggregate
formation and bacterial clearance (157). In contrast, CLEC-2
confers immune-inhibitory effects by dampening levels of
pro-inflammatory cyto- and chemokines as well as limiting
immune cell recruitment, inflammatory bleeding, and bacterial
dissemination, thus ameliorating organ damage in endotoxemia
and CLP (168). However, CLEC-2 also mediates inflammation-
driven thrombosis in sepsis (169). Interestingly, while GPVI is
not required for immune responses in endotoxemia, concomitant
deletion of GPVI and CLEC-2 reverses the exaggerated
inflammation and disease severity caused by lack of CLEC-2
alone. Thus, despite similar downstream signaling molecules,
GPVI and CLEC-2 seem to play opposite roles during sepsis,
most probably by regulating both the inflammatory response and
thrombosis (168).
Platelet-Derived Soluble Mediators in Sepsis
In addition to direct cellular interactions, activated platelets
secrete a plethora of soluble mediators from their granules
that potentially modulate host responses to sepsis. Nbeal2-
deficient mice, which lack α-granules, challenged with Klebsiella
pneumoniae-induced pneumosepsis exhibit similar circulating
platelet-leukocyte aggregates as wildtypes, but increased
pulmonary leukocyte influx and elevated multi-organ damage.
However, limiting Nbeal2-deficiency to the platelet compartment
does not reproduce these results, suggesting that platelet granule
content does not regulate host responses during Klebsiella
pneumoniae-induced pneumosepsis (170).
Nonetheless, multiple studies focusing on specific mediators
and using different sepsis models such as LPS-induced
endotoxemia or CLP reported significant contributions of
platelet granules proteins.
Platelet activation during sepsis triggers the release of
RANTES (CCL5) and platelet factor 4 (PF4, CXCL4) and
subsequent heteromer formation in the circulation. PF4 and
RANTES in turn stimulate alveolar macrophages to produce the
chemokines macrophage inhibitory protein-2 (MIP-2) and KC
(CXCL1; homologous to human IL-8/CXCL8), thus promoting
neutrophil recruitment but also edema formation (171–173).
Moreover, PF4 accelerates generation of activated protein C,
counteracting the increasing pro-coagulant state during sepsis
which may promote DIC. Accordingly, PF4 has been found to
increase survival in endotoxic shock (174).
In addition to cytokines and chemokines, serotonin released
from dense granules upon platelet activation may play a role
in sepsis. Using an FcγRIIA-humanized mouse model, it has
recently been discovered that immune complexes cause platelets
to transiently sequester to the lung, where they release serotonin
before returning to the circulation (119). As serotonin activates
endothelial cells, platelet-derived serotonin may subsequently
promote the adhesion and extravasation of neutrophils (175).
Additionally, platelet-derived HMGB1 has also recently been
implicated in augmenting leukocyte recruitment and bacterial
clearance in murine CLP (176).
The contribution of platelet release products to organ damage
during sepsis may not be limited to support of neutrophil
influx. During sepsis platelets carry intracellular granzyme B,
probably due to transcriptional alterations in megakaryocytes,
which causes local apoptosis at sites of platelet accumulation such
as the lungs, spleen, and kidneys, contributing to multiple organ
dysfunction and sepsis progression (177, 178).
These findings strongly underline the importance of platelet
activation for essential host responses during bacterial sepsis
such as immune cell recruitment, bacterial clearance, and
organ dysfunction. Indeed, mice lacking PAR-4 show reduced
levels of circulating PF4 48 h after infection with Streptococcus
pneumoniae. In line with the protective effect of PF4 in endotoxic
shock described above, these mice also suffer from increased
bacteremia and bacterial burden in the lungs, as well as
exacerbated pulmonary damage (161).
Pharmacological Platelet Inhibition During Sepsis
Given the availability of anti-platelet drugs, pharmacologic
targeting of platelet function represents an attractive approach to
mitigate platelet-assisted excessive inflammation that contributes
to sepsis progression.
Interestingly, inhibition of cyclooxygenase-1 (COX-1)
ameliorates thrombocytopenia and kidney dysfunction in
endotoxemia (179), yet transfusion of COX-1-deficient platelets
into platelet-depleted mice leads to worse survival than
transfusion of wildtype platelets (140). The impact of P2Y12 on
murine sepsis remains subject to discussion and depends on the
specific model used. Mice deficient in P2Y12 show a protective
role for P2Y12 in endotoxemia by ameliorating inflammation
and lung injury, although the results are not mirrored by the
use of a P2Y12 inhibitor (180). In contrast, blocking ADP
feedback by P2Y12 receptor antagonists, clopidogrel, prasugrel,
or ticagrelor, appears to be beneficial during sepsis, as it inhibits
platelet activation and binding to circulating neutrophils and
monocytes during pneumonia and CLP (181–183). This is
accompanied by diminished TNF-α and IL-1β levels, as well
as impeded neutrophil infiltration and platelet sequestration,
ultimately reducing lung and kidney injury, whereas bacterial
clearance does not seem to be affected by P2Y12 blockage
(144, 181–184). Furthermore, clopidogrel failed to ameliorate
thrombocytopenia in gram-negative pneumosepsis (185),
whereas in a modified CS model, clopidogrel also improved
sepsis-induced thrombocytopenia (186).
Thus, P2Y12 receptor antagonists show promising results in
pre-clinical studies to ameliorate sepsis pathogenesis, while the
potential of COX-1 inhibition remains unclear. Further, the
effects of anti-platelet medication on established sepsis as well
as the impact of P2Y12 blockers on bleeding risk have not
been addressed in detail thus far. Therefore, large clinical trials
are required to confirm if results from animal studies will be
translatable to the human patient setting.
Translational Limitations of Rodent Sepsis
Models
Mouse and rat models have proven to be valuable tools to
investigate cellular and molecular processes in sepsis. However,
animal models have inherent limitations independent of the
specific sepsis model and species that need to be taken into
consideration when evaluating and interpreting results.
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Age and Sex
Despite efforts to optimize, murine models do not appropriately
represent the archetypal septic patient which is an elderly person
with one or more co-morbidities. In contrast, mice are typically
used at the age of 6–12 weeks with most studies focusing
only on males. A literature screen for studies on platelets
in sepsis revealed an average age of 9 weeks with 60% of
studies being performed on males, 7% on females, 12% on both
sexes, and no specified information was available in 21% of
studies. Similarly, studies using rats as model organism also
mostly use adolescent males. Therefore, most in vivo studies
are more representative of healthy young men regarding age
and sex rather than heterogeneous patient populations. Time
and financial constraints are contributing to this bias as aging
animals are a costly investment. Further, reproducibility is higher
in young cohorts that vary less in weight and exposure to
environmental stressors.
Species
While a variety of species are currently used as animal models
in sepsis research, rodent models are the preferred approach
for studying platelets. LPS-induced endotoxemia and CLP are
widely used in both rats and mice. Rats are favorable models
for in vitro analyses of platelets as their larger body weight and
thus blood volume allows various concomitant measurements.
Indeed, ratmodels have unveiled a number of crucial intracellular
responses of platelets to sepsis, including activation of the NLRP3
inflammasome (187), upstream regulation of NADPH subunit
p47phox-dependent ROS production (188) and the contribution
of protein kinase C for platelet-mediated leukocyte infiltration
and organ injury (189). Furthermore, rats are more commonly
used when investigating effects of therapeutic intervention
strategies on clinical parameters e.g., hemodynamics. However,
genetic tools such as transgenic or knockout strains are rare in
rats, but readily available for mice. Thus, despite limited sample
material, murine models offer a wider range of experimental
approaches which are invaluable for investigating underlying
cell-specific molecular mechanisms. Of note, inflammatory
responses appear to be stronger and peak earlier in mice than
in rats (190). Therefore, interspecies differences have to be
considered when interpreting findings of different animal models
as well as their translation into the human setting.
Genetic Background
Another point to consider is the genetic background of mice
as individual inbred strains vary in their immune competence
due to polymorphisms and/or mutations, e.g., in TLRs or
complement factors.While the most widely used strains C57BL/6
and BALB/c express functional TLR4 and are therefore sensitive
to LPS, point mutations in the tlr4 gene have rendered some
strains (e.g., C3H/HeJ, C57BL10/ScSr) resistant to LPS (191),
making them useful tools to study endotoxin-independent host
responses (154). However, C57BL/6 are more susceptible to
fungal sepsis induced by zymosan or Candida albicans infection
than outbred CF-1 mice, showing weaker Th1 response and poor
survival (192). Further, mouse strains carrying loss-of-function
mutations of complement factor C5 such as DBA/1 or DBA/2
display altered susceptibility to certain bacterial strains.
Genetic background not only impacts on innate but also
on adaptive immunity. C57BL/6 mice tend to respond to
pathogens with an enhanced Th1-type response, leading to
increased phagocytic clearance of intracellular pathogens. In
contrast, BALB/c mice are skewed toward Th2-type responses
that support humoral immunity especially against extracellular
parasites (191).
Timeline
With the exception of CLP, rodent sepsis models rarely mirror
the timeline of sepsis pathogenesis in human patients. Injection
of PAMPs or live bacteria does not represent the slow outgrowth
and dissemination of bacteria from a center of infection, but
rather a sudden, overwhelming infection that typically leads
to death of the mice in a matter of hours or days. However,
adjustment of the infectious dose may yield a transient, non-
lethal infection that may be resolved within days. During
this timeframe, immediate host responses involving platelets,
coagulation and the innate immune system can be studied, as
thrombocytopenia may occur within minutes after infection and
induction of acute phase cytokines and neutrophil infiltration
toward sites of acute inflammation can be observed within hours.
Additionally, experimental setups seldom reproduce the
reality of sepsis in patients, where interventions have to be
efficient in counteracting established sepsis (137). Contrarily,
genetic modifications and drugs commonly take effect prior to
induction of experimental sepsis in mice. Therefore, observations
are only partly translatable to the patient situation.
Physiological Differences Between Mice and Humans
Most prominently, humans and mice differ considerably in their
circulating immune cell composition. In humans, neutrophils
constitute themost abundant leukocyte subpopulation (40–70%),
whereas mice show up to 84% lymphocytes (193), which may
impact on the relative contributions of innate and adaptive
immunity to host responses. As already mentioned, distinct
receptor expression regarding TLRs, PARs and Fc receptors
determines immune cell capacity of platelets. This makes it often
difficult to translate results from animal models to the clinical
situation. To overcome this problem, mice expressing human
receptors have been generated. While this was successful in some
cases (FcγRIIA) (194), other attempts failed so far to lead to
functional receptor expression (PAR-1) (195, 196). However, the
role of FcγRIIA was never addressed in a murine sepsis model.
Furthermore, while LPS challenge yields similar inflammatory
responses in mice and men, including cytokine production and
lymphopenia, humans are more sensitive to LPS than mice,
which necessitate the use of LPS concentrations in mouse models
that surpass those required to induce septic shock in humans
about 1,000–10,000-fold (197, 198).
Nevertheless, despite their pitfalls mouse models have been
immensely helpful to further our understanding of the role of
platelets in sepsis and have shed light on cause and effect of,
e.g., thrombocytopenia.
Frontiers in Immunology | www.frontiersin.org 13 July 2019 | Volume 10 | Article 1687
Assinger et al. Platelet in Sepsis
CONCLUSION
Although, it has been decades of research in sepsis, the gained
knowledge did not lead to the discovery of an effective treatment
approved in patients. Sepsis is a complex disease with multiple
players resulting in a very heterogeneous patient population with
different comorbidities, immune statuses, and susceptibilities
to infection. Many strategies are currently under investigation
to restore platelet count in sepsis patients. However, it is
still not known whether thrombocytopenia is a cause or a
consequence of sepsis severity and how platelets contribute
to sepsis progression. Moreover, as platelet receptors regulate
inflammatory hemostasis and infection in a stimulus- and organ-
dependent manner, a better understanding of the receptors and
the mechanisms involved is crucial for successful treatment.
Another factor to take into consideration is the immune status
of patients as different treatments might be required based on
the immune profile of the patients. While patients with SIRS
would benefit from an anti-inflammatory therapy, immune-
suppressed patients might benefit from an immuno-adjuvant
therapy. Anti-platelet therapies, in particular aspirin, seem
promising in experimental sepsis, however the risk of bleeding
has to be closely monitored. Currently two clinical trials address
the role of aspirin in patients and the outcome of these studies
are expected to further clarify the beneficial use of aspirin in
septic patients.
The use of mouse models shed light on new mechanisms in
sepsis, however many factors limit the translation to the human
setting. One major concern when targeting platelets is their dual
role in inflammation and hemostasis. Platelets are not only pro-
inflammatory cells but they also contribute to the resolution of
inflammation and tissue repair. Most of the studies performed
in mice use wild-type mice that lack FcγRIIA on platelets,
one of the major receptors on platelets regulating pathogen-
mediated activation, raising the question if FcγRIIA transgenic
mice are required to investigate infection-mediated sepsis in
mice. Moreover, comorbidities, age, and other factors might
need to be taken into consideration in experimental models to
reflect the clinical profile of the patients. In this context, animal
models associated with other comorbidities may provide a better
understanding of sepsis pathophysiology. A deeper knowledge
of the role of platelet receptors in sepsis along with randomized
clinical trials will determine the beneficial potential of different
anti-platelet therapies in patients.
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